Forge Therapeutics

Forge Therapeutics is dedicated to developing first-in-class antibiotics by leveraging an advanced drug discovery technology platform. Currently, the company focuses on developing small molecule inhibitors targeting metalloenzymes, with its lead product being a novel LpxC inhibitor. LpxC is a cytoplasmic zinc metalloenzyme found only in Gram-negative bacteria and is essential for their growth.